RK011

RK011 is a protein-based therapeutic candidate currently under development by RevolKa, a biotechnology company based in Tokyo, Japan. The drug was developed using RevolKa's proprietary protein engineering platform, which employs directed evolution to optimize protein functions for therapeutic applications. As of early 2024, RevolKa has not publicly disclosed the specific molecular target, mechanism of action, or the primary disease indication for RK011. The program is listed in the company's internal pipeline as having completed an undisclosed stage of research or technology development, indicating it is in the early stages of the drug discovery and development process.